Back to top

gene-therapy: Archive

Zacks Equity Research

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study

Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.

RARENegative Net Change ADMANegative Net Change FGENNegative Net Change ANVSPositive Net Change

Zacks Equity Research

Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex

Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.

VRTXNegative Net Change CRSPNegative Net Change ALPNPositive Net Change VERAPositive Net Change

Zacks Equity Research

Agilent (A) is Set for Analytica 2024 With Advanced Products

Agilent (A) plans to showcase its new products for analytical laboratories at Analytica 2024, boosting its overall product portfolio.

ANegative Net Change INCYPositive Net Change AMENegative Net Change AMATPositive Net Change

Zacks Equity Research

EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia

The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.

LGNDPositive Net Change ANIPNegative Net Change ADMANegative Net Change RCKTNegative Net Change

Zacks Equity Research

Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development

Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.

VRTXNegative Net Change ANIPNegative Net Change ADMANegative Net Change CRSPNegative Net Change